{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:42:25Z","timestamp":1791978145446,"version":"4.4.0"},"reference-count":33,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"TEDDY","award":["U01DK128847"],"award-info":[{"award-number":["U01DK128847"]}]},{"name":"Type 1 Diabetes TrialNet\/IASP"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The Islet Autoantibody Standardization Program (IASP) evaluates type 1 diabetes autoantibody assays through international interlaboratory comparison studies. This report describes 2024 IASP workshop results for multiplex assays that simultaneously measure multiple islet autoantibodies, increasingly adopted for population screening programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Participating laboratories analyzed coded sera from individuals with new-onset type 1 diabetes (n = 50), blood donors with no diabetes (n = 98), and replicate samples (n = 3). Performance was assessed using sensitivity, specificity, adjusted sensitivity at 95%, 99%, and 100% specificity, area under the receiver operating characteristic curve analysis (ROC-AUC), and partial ROC-AUC at 95% specificity (pAUC95).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Fifteen laboratories contributed results from 19 multiplex assays using five formats: antibody-dependent agglutination PCR (ADAP) (n = 6), bridge-ELISA (n = 8), electrochemiluminescence (n = 2), luciferase immunoprecipitation system (LIPS) (n = 1), and protein A luciferase\/solid-phase capture LIPS (n = 2). Median ROC-AUC was 0.98 across all platforms, with a pAUC95 of 0.048 against a theoretical maximum of 0.05. Laboratory-reported sensitivity ranged from 86% to 96% with specificity 81% to 100%. Standardized adjusted sensitivity at 99% specificity thresholds eliminated most false positives without compromising sensitivity, achieving 93\u201397% adjusted sensitivity. Bridge-ELISA platforms demonstrated potential for universal cutoff standardization, while ADAP showed substantial interlaboratory threshold variation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Multiplex assays demonstrated good overall performance for detecting islet autoantibodies and discriminating case subjects from control subjects. However, interlaboratory variability and platform-specific recognition patterns necessitate further standardization efforts. While not directly tested in this workshop, the results suggest that sequential testing strategies using complementary platforms may be necessary to achieve the stringent specificity required when these assays are used in a screening context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-1326","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:02:55Z","timestamp":1769180575000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":8,"title":["Interlaboratory Evaluation of Multiplex Autoantibody Assay Performance in the Islet Autoantibody Standardization Program 2024 Workshop"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-4509","authenticated-orcid":false,"given":"Ilaria","family":"Marzinotto","sequence":"first","affiliation":[{"name":"San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele 1 , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Pittman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Florida 2 , Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-2684","authenticated-orcid":false,"given":"Peter","family":"Achenbach","sequence":"additional","affiliation":[{"name":"Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health 3 , Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-5942","authenticated-orcid":false,"given":"Beena","family":"Akolkar","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases 4 , Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-8932","authenticated-orcid":false,"given":"Clive H.","family":"Wasserfall","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Florida 2 , Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-8445","authenticated-orcid":false,"given":"Vito","family":"Lampasona","sequence":"additional","affiliation":[{"name":"San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele 1 , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-2771","authenticated-orcid":false,"given":"Anna E.","family":"Long","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism, Translational Health Sciences, University of Bristol 5 , Bristol, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2026061812274777400_B1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"2026061812274777400_B2","doi-asserted-by":"crossref","first-page":"bvad160","DOI":"10.1210\/jendso\/bvad160","article-title":"Understanding islet autoantibodies in prediction of type 1 diabetes","volume":"8","author":"Jia","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026061812274777400_B3","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1210\/jc.2010-0293","article-title":"Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia","volume":"95","author":"Bonifacio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061812274777400_B4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/jaut.1997.0154","article-title":"A novel micro-assay for insulin autoantibodies","volume":"10","author":"Williams","year":"1997","journal-title":"J Autoimmun"},{"key":"2026061812274777400_B5","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.2337\/db08-0522","article-title":"A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes","volume":"57","author":"Wenzlau","year":"2008","journal-title":"Diabetes"},{"key":"2026061812274777400_B6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cca.2016.08.013","article-title":"3 Screen islet cell autoantibody ELISA: a sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8","volume":"462","author":"Amoroso","year":"2016","journal-title":"Clin Chim Acta"},{"key":"2026061812274777400_B7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/dia.2021.0517","article-title":"High-throughput multiplex electrochemiluminescence assay applicable to general population screening for type 1 diabetes and celiac disease","volume":"24","author":"He","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2026061812274777400_B8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.slast.2021.10.001","article-title":"Automation of a multiplex agglutination-PCR (ADAP) type 1 diabetes (T1D) assay for the rapid analysis of islet autoantibodies","volume":"27","author":"Cortez","year":"2022","journal-title":"SLAS Technol"},{"key":"2026061812274777400_B9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/db24-0814","article-title":"Comparative analysis of the sensitivity, specificity, concordance, and 5-year predictive power of diabetes-related autoantibody assays","volume":"74","author":"Krischer","year":"2025","journal-title":"Diabetes"},{"key":"2026061812274777400_B10","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2337\/db14-1693","article-title":"Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes","volume":"64","author":"Williams","year":"2015","journal-title":"Diabetes"},{"key":"2026061812274777400_B11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2337\/diabetes.52.5.1128","article-title":"Diabetes Antibody Standardization Program: first assay proficiency evaluation","volume":"52","author":"Bingley","year":"2003","journal-title":"Diabetes"},{"key":"2026061812274777400_B12","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/dc11-1161","article-title":"Diabetes Antibody Standardization Program: first evaluation of assays for autoantibodies to IA-2\u03b2","volume":"34","author":"Schlosser","year":"2011","journal-title":"Diabetes Care"},{"key":"2026061812274777400_B13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1373\/clinchem.2011.170662","article-title":"Diabetes Antibody Standardization Program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8","volume":"57","author":"Lampasona","year":"2011","journal-title":"Clin Chem"},{"key":"2026061812274777400_B14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1373\/clinchem.2019.304196","article-title":"Islet Autoantibody Standardization Program 2018 Workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance","volume":"65","author":"Lampasona","year":"2019","journal-title":"Clin Chem"},{"key":"2026061812274777400_B15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00125-023-05877-9","article-title":"Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops","volume":"66","author":"Marzinotto","year":"2023","journal-title":"Diabetologia"},{"key":"2026061812274777400_B16","first-page":"373","article-title":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects","volume":"79","author":"World Medical Association","year":"2001","journal-title":"Bull World Health Organ"},{"key":"2026061812274777400_B17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pro.4009","article-title":"Insulin binding to the analytical antibody sandwich pair OXI-005 and HUI-018: epitope mapping and binding properties","volume":"30","author":"Johansson","year":"2021","journal-title":"Protein Sci"},{"key":"2026061812274777400_B18","unstructured":"R Core Team\n          . R: a language and environment for statistical computing. Version 4.5.0. Accessed 11 April 2025. Available from https:\/\/www.R-project.org\/"},{"key":"2026061812274777400_B19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2026061812274777400_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: improved estimation and validation of optimal cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Soft"},{"key":"2026061812274777400_B21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"key":"2026061812274777400_B22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.16354","article-title":"Type 1 diabetes risk factors, risk prediction and presymptomatic detection: evidence and guidance for screening","volume":"27","author":"Bonifacio","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026061812274777400_B23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-024-06205-5","article-title":"Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes","volume":"67","author":"Phillip","year":"2024","journal-title":"Diabetologia"},{"key":"2026061812274777400_B24","doi-asserted-by":"crossref","first-page":"e011144","DOI":"10.1136\/bmjopen-2016-011144","article-title":"Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study","volume":"6","author":"Raab","year":"2016","journal-title":"BMJ Open"},{"key":"2026061812274777400_B25","doi-asserted-by":"crossref","first-page":"105144","DOI":"10.1016\/j.ebiom.2024.105144","article-title":"Childhood screening for type 1 diabetes comparing automated multiplex Antibody Detection by Agglutination-PCR (ADAP) with single plex islet autoantibody radiobinding assays","volume":"104","author":"Lind","year":"2024","journal-title":"EBioMedicine"},{"key":"2026061812274777400_B26","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"2026061812274777400_B27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061812274777400_B28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jama.2019.21565","article-title":"Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany","volume":"323","author":"Ziegler","year":"2020","journal-title":"JAMA"},{"key":"2026061812274777400_B29","doi-asserted-by":"crossref","first-page":"e15490","DOI":"10.1111\/dme.15490","article-title":"Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening\u2014the EarLy Surveillance for Autoimmune diabetes (ELSA) study","volume":"42","author":"Quinn","year":"2025","journal-title":"Diabet Med"},{"key":"2026061812274777400_B30","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1111\/dom.15779","article-title":"Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy","volume":"26","author":"Cherubini","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061812274777400_B31","doi-asserted-by":"crossref","first-page":"e088522","DOI":"10.1136\/bmjopen-2024-088522","article-title":"EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents","volume":"15","author":"Hoffmann","year":"2025","journal-title":"BMJ Open"},{"key":"2026061812274777400_B32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-2003","article-title":"Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado","volume":"43","author":"McQueen","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061812274777400_B33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc24-2443","article-title":"Islet autoantibody screening throughout Australia using in-home blood spot sampling: 2-year outcomes of Type1Screen","volume":"48","author":"Wentworth","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/4\/607\/855177\/dc251326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/4\/607\/855177\/dc251326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:27:56Z","timestamp":1781800076000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/4\/607\/164370\/Interlaboratory-Evaluation-of-Multiplex"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-1326","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}